Bibapcitide (CAS No. 153507-46-1) | GMP Research Peptide for Thrombosis Inhibition

描述

Product Description

Bibapcitide is a synthetic peptide composed of 26 amino acids, specifically designed as an inhibitor of thrombosis. Its development reflects ongoing scientific efforts to better understand and control the mechanisms of blood clot formation, a process that plays a central role in both normal hemostasis and pathological conditions such as myocardial infarction, ischemic stroke, pulmonary embolism, and venous thromboembolism.

Scientific Background

Thrombosis is the pathological formation of blood clots within blood vessels, obstructing blood flow and potentially leading to life-threatening events. At the core of thrombus formation lies the interplay between platelets, coagulation factors, and vascular endothelium. Platelets adhere to sites of vascular injury, become activated, and aggregate to form a platelet plug. While this process is essential for wound healing, excessive platelet aggregation can lead to arterial occlusion and ischemic damage.

Bibapcitide was developed as a research tool to specifically target these thrombotic pathways. By interfering with platelet aggregation and fibrin clot formation, it provides a model system for studying antithrombotic mechanisms and testing therapeutic strategies.

Structural Characteristics

Bibapcitide is a 26 amino acid peptide, which makes it considerably larger than many short therapeutic peptides but smaller than full-length proteins. This structural balance provides several advantages:

• Defined sequence for reproducibility across experiments

• Enhanced specificity in targeting platelet interactions

• Synthetic production for consistent purity and scalability

• Flexibility in formulation, allowing modifications for enhanced stability or conjugation

Research Value

Bibapcitide is widely studied in:

• Cardiovascular research – evaluating prevention of arterial thrombosis

• Hematology – investigating platelet function and coagulation cascades

• Pharmacology – testing antithrombotic drug combinations

• Translational medicine – serving as a peptide-based lead for therapeutic innovation

As thrombosis remains a leading cause of morbidity and mortality worldwide, Bibapcitide represents a highly relevant peptide for advancing our understanding of clot biology and improving antithrombotic therapies.

Product Specifications

Specification Notes

• Purity: ≥ 98% purity ensures low contamination risk in sensitive coagulation assays.

• Sequence length: 26 amino acids make Bibapcitide highly specific while retaining manageable synthesis and handling properties.

• Solubility: Broad solubility in physiological buffers facilitates in vitro and in vivo use.

• Applications: Especially valuable in platelet function assays, clotting studies, and in vivo thrombosis models.

Mechanism of Action & Research Applications

Mechanism of Action

Bibapcitide functions as a direct inhibitor of thrombosis by interfering with platelet aggregation. Research indicates it works through:

1. Blocking platelet adhesion at the vascular injury site.

2. Preventing activation and shape change of platelets, which is normally triggered by ADP, thrombin, or collagen.

3. Inhibiting fibrin cross-linking, thereby reducing clot stability.

4. Maintaining vascular patency by preventing occlusive thrombus formation.

Unlike classical anticoagulants (e.g., heparin, warfarin), which target coagulation pathways, Bibapcitide focuses primarily on the platelet component of thrombosis, making it an excellent research tool for dissecting platelet-specific mechanisms.

Research Applications

1. Cardiovascular Disease Models
   Used in preclinical research to study myocardial infarction, unstable angina, and ischemic stroke, where platelet-driven clots play a central role.

2. Platelet Function Studies
   Allows researchers to measure platelet adhesion, spreading, and aggregation under controlled conditions.

3. Pharmacological Testing
   Serves as a model antithrombotic agent for combination studies with anticoagulants, antiplatelet drugs (aspirin, clopidogrel), or thrombolytics.

4. Vascular Biology Research
   Provides insights into how endothelial injury leads to thrombosis and how targeted inhibition can preserve vascular flow.

5. Translational Oncology
   Cancer patients often suffer from thromboembolic complications. Bibapcitide enables the study of tumor-associated thrombosis and potential intervention strategies.

6. Drug Discovery Platform
   Because it is a peptide with well-defined activity, Bibapcitide is used as a template for analogs or peptidomimetics with enhanced pharmacokinetics.

7. Comparative Hematology
   Used in both small and large animal models to compare cross-species platelet biology and thrombotic responses.

Broader Impact

Bibapcitide contributes significantly to modern hematology and cardiovascular science. By enabling targeted analysis of thrombosis, it supports the development of next-generation antithrombotic agents with improved safety profiles, aiming to reduce the risk of bleeding while maintaining strong antithrombotic effects.

Side Effects (Research Context Only)

Although Bibapcitide is not intended for clinical use, certain laboratory observations highlight potential side effects:

1. Excessive Antithrombotic Activity
   Over-inhibition of platelet aggregation may lead to prolonged bleeding times in in vivo models.

2. Hemostatic Imbalance
   Disruption of normal clotting balance may result in experimental bleeding complications.

3. Immune Reactions
   As a synthetic peptide, Bibapcitide may elicit antibody formation in repeated or long-term animal studies.

4. Off-target Effects
   High concentrations could interfere with other platelet signaling pathways or non-platelet proteins.

5. Species-Specific Responses
   Variations in platelet receptor expression across species may alter activity profiles.

6. Combination Studies
   When tested with anticoagulants or thrombolytics, exaggerated bleeding risk may occur in models.

7. Stability-Linked Issues
   Degradation due to improper storage or repeated freeze-thaw cycles may reduce activity and introduce artifacts.

These effects are strictly observed in controlled research models and do not imply clinical outcomes.

Disclaimer

For laboratory research use only. Not for human or veterinary use.

Keywords

• Bibapcitide

• Bibapcitide CAS 153507-46-1

• 26 amino acid thrombosis inhibitor peptide

• Antithrombotic peptide

• Platelet aggregation inhibitor peptide

• Cardiovascular research peptide

• Hematology peptide

• GMP peptide supplier

• Synthetic peptide for vascular biology

• Research-use-only peptide